SH-1028, a Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR T790M–Positive NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
J Thorac Oncol 2022 Jul 05;[EPub Ahead of Print], A Xiong, S Ren, H Liu, L Miao, L Wang, J Chen, W Li, R Li, X Wang, Z Lu, D Wang, X Wu, Z Liu, L Xing, Y Mao, C Liu, A Zeng, H Niu, Y Du, Y Sun, Y Pan, Y Hu, X Zhang, X Chen, Z Ma, N Li, J Zhang, M Zhao, X Li, F Ye, M Li, G Yu, X Zhang, J Min, D Han, J Li, C ZhouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.